The baseline characteristics of the primary cohort and the validation cohort
| The primary cohort (n = 95) No. of patients (%) | The validation cohort (n = 55) No. of patients (%) | P-value | |
|---|---|---|---|
| Sex | 0.579 | ||
| Male | 68 (71.6) | 37 (67.3) | |
| Female | 27 (28.4) | 18 (32.7) | |
| Age (years) | 0.342 | ||
| Median | 58 | 59 | |
| Range | 38–81 | 37–78 | |
| Esophagectomy | 0.729 | ||
| R0 | 87 (91.6) | 52 (94.5) | |
| R1 | 8 (8.4) | 3 (5.5) | |
| Grade | 0.870 | ||
| G1 | 9 (9.5) | 4 (7.3) | |
| G2 | 69 (72.6) | 40 (72.7) | |
| G3 | 17 (17.9) | 11 (20.0) | |
| T Stage | 0.340 | ||
| T1a + T1b | 14 (14.7) | 7 (12.7) | |
| T2 | 30 (31.6) | 18 (32.7) | |
| T3 | 33 (33.7) | 25 (45.5) | |
| T4a | 18 (19.0) | 5 (9.1) | |
| N Stage | 0.272 | ||
| N0 | 64 (67.4) | 29 (52.8) | |
| N1 | 18 (18.9) | 13 (23.7) | |
| N2 | 10 (10.5) | 11 (20.0) | |
| N3 | 3 (3.2) | 2 (3.5) | |
| TNM Stage | 0.656 | ||
| IA + IB | 20 (21.0) | 8 (14.5) | |
| IIA + IIB | 34 (35.8) | 20 (36.4) | |
| IIIA+IIIB | 32 (33.7) | 23 (41.8) | |
| IVA | 9 (9.5) | 4 (7.3) |